BriaCell Therapeutics Corp. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCTX Nasdaq 2830 briacell.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BriaCell Therapeutics Corp.

Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)? - Jul 17th, 2026 9:15 pm
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer - Jul 16th, 2026 5:30 am
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™ - Jul 15th, 2026 5:30 am
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™ - Jul 7th, 2026 5:30 am
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™ - Jun 25th, 2026 5:30 am
BriaCell Therapeutics Announces Closing of Offering - Jun 2nd, 2026 2:05 pm
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting - Jun 1st, 2026 7:57 am
BriaCell Presents Positive Clinical Data at ASCO 2026 - Jun 1st, 2026 5:30 am
BriaCell Therapeutics Announces Pricing of Offering - May 31st, 2026 5:59 pm
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer - May 26th, 2026 5:30 am
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 - May 22nd, 2026 5:30 am
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ - May 15th, 2026 5:30 am
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies - May 14th, 2026 6:45 am
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer - May 14th, 2026 5:30 am
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - May 13th, 2026 5:30 am
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients - May 12th, 2026 5:30 am
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - May 7th, 2026 5:30 am
BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study - May 6th, 2026 5:56 am
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer - May 6th, 2026 5:30 am
BriaCell Announces Six Clinical Data Presentations at ASCO 2026 - Apr 27th, 2026 5:30 am